SAN FRANCISCO–(BUSINESS WIRE)–Verana Health, a healthcare technology and analytics innovator transforming multi-specialty clinical data into real-world evidence, today unveiled ground-breaking research during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. In a first-of-its kind study, Verana Health demonstrated that it was able to successfully use real world data (RWD) to replicate primary outcome measures of two large-scale randomized controlled trials (RCTs) in ophthalmology—the VIEW 1 and VIEW 2 (VIEW 1/2) pivotal trials. VIEW 1/2 led to the clearance by the Food & Drug Administration (FDA) of aflibercept (EYLEA→, Regeneron) for the treatment of neovascular age-related macular degeneration (wet AMD) in 2011.
In this electronic health record (EHR) based registry study, investigators replicated the study design and evaluated the outcomes using RWD contained in the American Academy of Ophthalmology IRIS→ Registry (Intelligent Research in Sight), the world’s largest single-specialty clinical database. The same inclusion and exclusion criteria of the VIEW 1/2 studies were successfully applied to the IRIS Registry and resulted in the identification of 4779 patients that could be compared to the 1632 subjects in the VIEW 1/2 studies. The proportion of eyes losing